Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.45 |
| ▸ | HTR1F | P30939 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 2/20 | 0.44 |
| ▸ | JAK1 | P23458 | 2/20 | 0.44 |
| ▸ | TYK2 | P29597 | 2/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.44 |
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.43 |
| ▸ | PI4KA | P42356 | 1/20 | 0.43 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23539710 | 0.84 | ALDH1A1 (0.43) | NPC1ALDH1A1RAB9AGAASMN1; SMN2 | |
| SCHEMBL108305 | 0.81 | P2RX7 (0.50) | NPC1ALDH1A1RAB9AGAASMN1; SMN2 | |
| SCHEMBL22854273 | 0.81 | NPC1 (0.45) | NPC1ALDH1A1RAB9AGAASMN1; SMN2 | |
| SCHEMBL6419679 | 0.80 | ANO1 (0.47) | NPC1ALDH1A1RAB9AGAASMN1; SMN2 | |
| SCHEMBL19249270 | 0.80 | GRM5 (0.55) | NPC1ALDH1A1RAB9AGAASMN1; SMN2 | |
| SCHEMBL23708908 | 0.80 | CNR1 (0.46) | NPC1ALDH1A1RAB9AGAASMN1; SMN2 | |
| SCHEMBL29503927 | 0.80 | ANO1 (0.47) | NPC1ALDH1A1RAB9AGAASMN1; SMN2 | |
| SCHEMBL30549449 | 0.80 | TYK2 (0.56) | JAK2JAK1TYK2PDE4DGRM5 | |
| SCHEMBL6874915 | 0.79 | NPC1 (0.69) | NPC1ALDH1A1RAB9AGAASMN1; SMN2 | |
| SCHEMBL25412400 | 0.79 | P4HTM (0.47) | NPC1ALDH1A1RAB9AGAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747256-A1 | PARP1 INHIBITOR COMPOUNDS | Duke Street Bio Limited (GB) | 2026-05-27 | — | — | EP | disclosed |
| EP-4674841-A2 | PHARMACEUTICAL COMPOUND | Duke Street Bio Limited (GB) | 2026-01-07 | — | — | EP | disclosed |
| WO-2025073583-A1 | PARP1 INHIBITOR COMPOUNDS | Duke Street Bio Limited (GB) | 2025-04-10 | — | — | WO | disclosed |
| CN-119684303-A | Heterocyclic compound of difunctional degradable androgen receptor and application thereof | 上海超阳药业有限公司 | 2025-03-25 | — | — | CN | disclosed |
| CN-119431361-A | Preparation method of PARP1 inhibitor | 上海喀露蓝科技有限公司 | 2025-02-14 | — | — | CN | disclosed |
| WO-2025026745-A1 | PARP1 INHIBITOR COMPOUNDS | Duke Street Bio Limited (GB) | 2025-02-06 | — | — | WO | disclosed |
| CN-118973578-A | Pharmaceutical compounds | 杜克街生物有限公司 | 2024-11-15 | — | — | CN | disclosed |
| EP-4444305-A2 | PHARMACEUTICAL COMPOUND | Duke Street Bio Limited (GB) | 2024-10-16 | — | — | EP | disclosed |
| WO-2024067691-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | 中国医药研究开发中心有限公司 | 2024-04-04 | — | — | WO | disclosed |
| WO-2023156386-A2 | PHARMACEUTICAL COMPOUND | Duke Street Bio Limited (GB) | 2023-08-24 | — | — | WO | disclosed |
| EP-2239253-B1 | NOVEL PHENYLPYRROLE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2013-06-19 | — | — | EP | disclosed |
| WO-2013083557-A1 | 6-DIFLUOROMETHYL-5,6-DIHYDRO-2H-[1,4]OXAZIN-3-AMINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2013-06-13 | — | — | WO | disclosed |
| US-20130109683-A1 | 5,6-DIHYDRO-2H-[1,4]OXAZIN-3-YL-AMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA NV (US) | 2013-05-02 | — | — | US | disclosed |
| US-20130109683-A1 | 5,6-DIHYDRO-2H-[1,4]OXAZIN-3-YL-AMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA NV (US) | 2013-05-02 | — | — | US | disclosed |
| US-8415359-B2 | Phenylpyrrole derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-04-09 | — | — | US | disclosed |
| US-20120022075-A1 | NOVEL PHENYLPYRROLE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-01-26 | — | — | US | disclosed |
| WO-2011154431-A1 | 5,6-DIHYDRO-2H-[1,4]OXAZIN-3-YL-AMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2011-12-15 | — | — | WO | disclosed |
| US-8017610-B2 | Phenylpyrrole derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-09-13 | — | — | US | disclosed |
| US-20110003787-A1 | NOVEL PHENYLPYRROLE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-01-06 | — | — | US | disclosed |
| EP-2239253-A1 | NOVEL PHENYLPYRROLE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2010-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003787-A1 | NOVEL PHENYLPYRROLE DERIVATIVE | GCKR, GCK, SLC5A1 | NPC1 2719/4885ALDH1A1 1098/4885RAB9A 3083/4885 |
| US-20120022075-A1 | NOVEL PHENYLPYRROLE DERIVATIVE | GCKR, GCK, SLC5A1 | NPC1 2719/4885ALDH1A1 1098/4885RAB9A 3083/4885 |
| US-20130109683-A1 | 5,6-DIHYDRO-2H-[1,4]OXAZIN-3-YL-AMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | BACE2, BACE1, PSEN2 | NPC1 1993/4885ALDH1A1 3229/4885RAB9A 2328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.